Description: It goes without saying that the analysis of data is a key aspect of actuarial practice, but do traditional actuarial approaches allow us to see the whole picture? Effective data analysis is also key to the identification of health disparities and measuring progress on health equity. Actuaries and others analyzing data for health equity purposes find themselves looking at data differently.

Description: In this session, we will review how the previous and current concerns of pharmacy actuaries will affect the forecasting and review of upcoming pipeline events. After this session, attendees will have a broader understanding of the implications of what is coming next in the pharmacy pipeline and how they can be thinking about it.

Description: Every patient leaving the hospital has personal life-context circumstances that impact their chances of successful recovery and complications can be costly. Complex care management impacts over 50 percent of health care spend, with the admitted commercial population driving 37 percent of spend or $177M per 100,000 lives and the Medicare population driving 53 percent of spend or $600 million per 100,000 lives. The stakes are high, but existing care management solutions are mostly clinical and navigation call centers provide fragmented and outdated patient management systems, and do not address individual life-context. Discharged patients therefore remain underengaged and undercompliant, leading to costly complications. Innovative technology can help enable and integrate systems and existing infrastructure to leverage evidence-based contextualized care that will enhance care management, improve efficiency, and drive a better experience and outcomes for patients. This technology helps codifies life context, dynamically stratifying and engaging members digitally and telephonically helping virtual care teams to be more effective and efficient. In a recent randomized clinical trial, this technology and approach has shown a 50 percent reduction in the total cost of care, cutting the average and total cost of readmission, increasing virtual care team impact and member engagement and trust.

Description: Explore historical trends in enrollment, carrier participation, and competition over the first 10 years of the individual marketplace as a basis to frame what the future could hold for the next 10 years. Draw parallels to other lines of business (e.g., Medicare Advantage, employer group) as we look at how the market may evolve and the capabilities required to succeed. This session would be valuable for anyone interested in consumer purchasing behavior, quality and risk adjustment, employer benefits, provider dynamics, and the individual market more broadly. By attending this this session, you will be able to articulate the impact of recent legislation and regulatory actions on the Individual market, including subsidies, employer funding vehicles (e.g., ICHRA), distribution channels, and product requirements.

Description: Develop a better understanding of specialty drug trends and their increasing healthcare costs for more than the past decade by attending this webcast. With the introduction of price competition, you will see changes in the market for biosimilar products and patent-protected drugs. For example, the drug Humira will be gaining 10 biosimilar competitors in 2023. Alone, Humira can represent over 20% of total pharmacy spend for health plans. Join us and discover how price competition is a turning point for the pharmaceutical industry and will define its direction for the next decade.

Description: Investigate the importance of collaboration with accounting, underwriting, sales, marketing and other professions as an actuary when you attend this webcast. Cross-functional positions can cause unique challenges to arise, like various experts attempting to balance growth and profitability. Discover an opportunity to learn about relevant ASOPs and dive deeper into contemporary examples that highlight specific professionalism issues that can develop.

Description: What if a blood test can detect more than 50 types of cancer, including those in early stages? A biotech company, GRAIL, has developed the first-to-market Multi-Cancer Early Detection test and launched it for commercial use in 2021. Join us to learn how Munich Re and GRAIL are partnering to bring its Galleri test to the life insurance industry. You will also explore how we as an industry can help save lives by detecting cancer earlier and share perspectives on some early findings and cost-benefit analysis

Description: A new wave of biosimilar launches is creating downward pressure on average sales prices (ASPs), disrupting reimbursement to providers, providing opportunities and challenges to payers and GPOs, and upending the gross-to-net math for manufacturers. In this session, we will explore the implications of the ASP death spiral on the drug supply chain and its interplay with price transparency efforts.

Description: Ask all your questions related to value-based care to a panel of experts. How do we handle a tough negotiation? How do you measure impact in a value contract? What analytics should be considered for specific contract evaluation? What are current trends in value-based care in Medicare, commercial, and Medicaid? We've got a panel of experts to help you get answers.

Description: Court is in session and you are the jury! Follow along as challenging aspects of actuarial professionalism are explored in a court-like setting. Deliberate among your peers based on what you already know from your own experience as well as what you learn in this session, and then deliver your verdict accordingly.